The Brazilian policy of withholding treatment for ADHD is probably increasing health and social costs
dc.contributor.author | Maia, Carlos Renato Moreira | pt_BR |
dc.contributor.author | Stella, Steffan Frosi | pt_BR |
dc.contributor.author | Mattos, Paulo | pt_BR |
dc.contributor.author | Cruz, Luciane Nascimento | pt_BR |
dc.contributor.author | Polanczyk, Guilherme Vanoni | pt_BR |
dc.contributor.author | Rohde, Luis Augusto Paim | pt_BR |
dc.contributor.author | Polanczyk, Carisi Anne | pt_BR |
dc.date.accessioned | 2016-08-24T02:16:10Z | pt_BR |
dc.date.issued | 2015 | pt_BR |
dc.identifier.issn | 1516-4446 | pt_BR |
dc.identifier.uri | http://hdl.handle.net/10183/147593 | pt_BR |
dc.description.abstract | Objective: To estimate the economic consequences of the current Brazilian government policy for attention-deficit/hyperactivity disorder (ADHD) treatment and how much the country would save if treatment with immediate-release methylphenidate (MPH-IR), as suggested by the World Health Organization (WHO), was offered to patients with ADHD. Method: Based on conservative previous analyses, we assumed that 257,662 patients aged 5 to 19 years are not receiving ADHD treatment in Brazil. We estimated the direct costs and savings of treating and not treating ADHD on the basis of the following data: a) spending on ADHD patients directly attributable to grade retention and emergency department visits; and b) savings due to impact of ADHD treatment on these outcomes. Results: Considering outcomes for which data on the impact of MPH-IR treatment are available, Brazil is probably wasting approximately R$ 1.841 billion/year on the direct consequences of not treating ADHD in this age range alone. On the other hand, treating ADHD in accordance with WHO recommendations would save approximately R$ 1.163 billion/year. Conclusions: By increasing investments on MPH-IR treatment for ADHD to around R$ 377 million/ year, the country would save approximately 3.1 times more than is currently spent on the consequences of not treating ADHD in patients aged 5 to 19 years. | en |
dc.format.mimetype | application/pdf | |
dc.language.iso | por | pt_BR |
dc.relation.ispartof | Revista brasileira de psiquiatria (1999). São Paulo. Vol. 37, n. 1 (jan./mar. 2015), p. 67–70 | pt_BR |
dc.rights | Open Access | en |
dc.subject | Attention-deficit/hyperactivity disorder | en |
dc.subject | Transtorno do déficit de atenção com hiperatividade | pt_BR |
dc.subject | Análise custo-eficiência | pt_BR |
dc.subject | Social and political issues | en |
dc.subject | Costs and cost analysis | en |
dc.subject | Child psychiatry | en |
dc.subject | Central nervous system stimulants | en |
dc.title | The Brazilian policy of withholding treatment for ADHD is probably increasing health and social costs | pt_BR |
dc.type | Artigo de periódico | pt_BR |
dc.identifier.nrb | 000998345 | pt_BR |
dc.type.origin | Nacional | pt_BR |
Este item está licenciado na Creative Commons License
-
Artigos de Periódicos (38920)Ciências da Saúde (10529)